{
  "docId": "019de076-f8dc-71cb-8c77-d8d892e68e05",
  "docSlug": "d63a60a343bcaadeb9fd5627a42c66c9",
  "documentTitle": "CARGO Therapeutics | IPO Presentation Deck | 29 slides",
  "authorId": "cargo-therapeutics",
  "authorName": "CARGO Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 5,
  "pageCount": 29,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "The slide uses a chevron-based layout to categorize key company pillars.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f8dc-71cb-8c77-d8d892e68e05/5",
  "deckHref": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05",
  "deckJsonHref": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05.json",
  "deckAnchorHref": "/decks/019de076-f8dc-71cb-8c77-d8d892e68e05#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.26,
        "y": 0.76
      },
      "kind": "list",
      "text": "Co-founded in 2021 by globally recognized pioneers; Seasoned, strong leadership team; $200M Series A preferred stock round in February 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "21b73b8b-2529-486b-8eae-b5026ee856c2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.26,
        "y": 0.52
      },
      "kind": "list",
      "text": "Leveraging proprietary cell engineering platform technologies to develop a pipeline of programs; CRG-023, an IND-enabling stage tri-specific targeting CD19, CD20 and CD22",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56de476a-9c81-4d5f-930c-7b08c21cde7a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.7,
        "x": 0.26,
        "y": 0.215
      },
      "kind": "list",
      "text": "Positive Phase 1 results in CD19 CAR T R/R LBCL – 53% CR rate (20 of 38 patients) with ongoing durable responses in 85% of CRs (17 of 20) at median follow-up of 23 months; 120+ patients have been dosed; Initiated Phase 2; Stanford granted Breakthrough Therapy Designation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a8d551e-2612-4ae9-b062-0b2d43097275",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.04,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note: As of May 3, 2023 data cutoff date",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4938077-f5f8-4e75-a71e-42f1389c4209",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "CARGO – developing potentially curative cell therapies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6dc504c3-8afa-45d7-aaed-d8d2700f266e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "0328cb50-839e-405e-8e0f-ec758dae938c",
      "evidence": "list/bullet: Positive Phase 1 results in CD19 CAR T R/R LBCL – 53% CR rate (20 of 38 patients) with ongoing durable responses in 85% of CRs (17 of 20) at median follow-up of 23 months; 120+ patients have been dosed; Init",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 28,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "f28bc1f0-250a-416d-b5fe-d9a40f469b97",
      "evidence": "The loop is opened on slide 4 and closed on slide 28",
      "position": 1,
      "objective": "Why does CARGO Therapeutics exist? What is the company's vision?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}